1. Home
  2. ZURA vs AGNT Comparison

ZURA vs AGNT Comparison

Compare ZURA & AGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

N/A

Current Price

$0.97

Market Cap

455.4M

Sector

Health Care

ML Signal

N/A

Logo AGNT Inc. Common Stock

AGNT

AGNT Inc. Common Stock

N/A

Current Price

$2.43

Market Cap

439.8M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ZURA
AGNT
Founded
2022
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
439.8M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
ZURA
AGNT
Price
$0.97
$2.43
Analyst Decision
Strong Buy
Buy
Analyst Count
7
3
Target Price
★ $8.00
$5.25
AVG Volume (30 Days)
★ 6.7M
1.6M
Earning Date
10-27-2026
11-05-2026
Dividend Yield
N/A
★ 7.94%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $500,147,681.00
Revenue This Year
N/A
$4.04
Revenue Next Year
N/A
$4.09
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 220.39
52 Week Low
$0.92
$2.47
52 Week High
$7.25
$5.79

Technical Indicators

Market Signals
Indicator
ZURA
AGNT
Relative Strength Index (RSI) 24.64 29.74
Support Level $0.93 N/A
Resistance Level $5.97 $4.20
Average True Range (ATR) 0.23 0.28
MACD -0.15 -0.09
Stochastic Oscillator 0.46 0.51

Price Performance

Historical Comparison
ZURA
AGNT

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About AGNT AGNT Inc. Common Stock

AGNT Inc is a multi-model real estate platform, with brands including eXp Realty, eXp Commercial, NextHome, FrameVR.io, and SUCCESS Enterprises. The group prioritizes transparency, innovation, and long-term value for agents, franchise owners, staff, and shareholders.

Share on Social Networks: